Pr Fabrice Bauer
@NormandIcc
Followers
52
Following
145
Media
12
Statuses
113
Advanced Heart Failure and Pulmonary Hypertension. Structural Heart Failure Disease. Cardiac Amylodosis
Rouen University Hospital
Joined October 2021
🔥 Big news from CADENCE — positive topline results hitting all the right notes. Targeting PH in heart failure may finally be finding its rhythm. 🫀🎵 @mardigomberg @jeanlucvachiery
https://t.co/mDNLNlFl2S
businesswire.com
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF
4
18
54
“With an ever-growing population of #HeartFailure patients, it seems counterintuitive that fewer cardiology fellows are pursuing careers in this field,” writes Stephanie Golob, MD, in a recent #CardiologyMag article. Read more: https://t.co/OC8CJ4PDVf
#ACCFIT
0
1
6
Remote pulmonary artery pressure-guided management of patients with heart failure: A clinical consensus statement of the #HFA of the @escardio
@MarcoMetra
https://t.co/mgk4bi8qzw
#EJHF @HanCardiomd @AmrAbdin10 @GiuseppeGalati_
0
24
52
🗞️ The use of #LVEF in the diagnosis and management of #heartfailure. A clinical consensus statement of the #HFA of @escardio, the @HFSA & the @jhfs2024
@ESC_Journals @GiuseppeGalati_
@AmrAbdin10 @HanCardiomd
https://t.co/RxZkr4gHEd
0
42
97
Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25. Check out the key findings ➡️ https://t.co/hVqEY34Uie
0
32
97
If you missed the LBCT session this morning, catch up with #ACC25 and follow the meeting coverage here ➡️
acc.org
This page features full coverage of the latest science from ACC.25, including trial summaries, news stories, journal scans, slides, videos and more.
Randomized study of IV iron for HF: Ferric carboxymaltose- FAIR HF 2 trial- directionally supportive but not quite meeting statistical significance for CV death or HF; however meta-analysis of iv iron in HF supportive of benefit for HF hosp and CV death. @ACCinTouch #ACC25
1
7
29
In this RCT of 1766 patients with #cancer and history of #VTE, extended apixaban 2.5 mg bid was non-inferior (NIF margin 2.0 for upper 95% CI) to apixaban 5.0 mg bid in preventing recurrent VTE Hierarchical testing demonstrated superiority in ⬇️bleeding #APICAT #ACC25
🎙️NEW #ACC25 Late-Breaker Discussion 💫Prof @isabellemahe1 joins host @hvanspall to discuss the API-CAT trial. 📽️Watch here👉 https://t.co/Udkv8VgqMJ
#Anticoagulation #Apixaban #VTE #CardioTwitter
0
14
32
ALIGN-AR: Among patients with aortic regurgitation undergoing #TAVR with the Trilogy valve, the rate of mortality at one year was 8.1%, significantly lower than the prespecified goal of 25% to show noninferiority. #ACC25 Learn more: https://t.co/gkMpHssuqS
0
8
31
From @ACCinTouch HeartHouse Round Table to @JACCJournals Clinical Guidance & Improving outcomes! Phenomenal #ACC2025 Cardiogenic Shock discussion. Proud of @ISHVnews shining stars @ShashankSinhaMD @vbluml @behnam_tehrani @coconnormd @InovaCVfellows
0
1
3
#ACC25 #CircSimPub Two-year follow-up results of TRILUMINATE trial indicate significant reduction in tricuspid regurgitation severity & decreased HF hospitalization rates with tricuspid TEER compared to medical therapy. https://t.co/H9ef9xgLtt
#AHAJournals @hahn_rt @tavrkapadia
1
55
98
A visionary in structural heart disease & interventional echocardiography, Dr. Rebecca T. Hahn has revolutionized valve imaging & percutaneous therapies. Her impact on research, training & innovation is unmatched. Read her inspiring path to discovery! https://t.co/CtHjZznNLd
5
34
139
🔥🔥First LBCT session of #THT2025 - @JavedButler1 shares 2 year outcome data from the ALT-FLOW single-arm EFS. Significant ⬆️ in KCCQ, 6MWD and ⬇️in NYHA FC. Stable RA/RV size/function. Similar improvements in those with PVR < or > 2 WU. Sim pub @JACCJournals:
1
8
19
Nice to see 3 of my students belonging to this so-important group
🇫🇷🫶🏻🤙🏼
0
0
5
Rapport de la cours des comptes sur la mise en place des #IPA en 2023 Sans surprise 2 freins majeurs 1️⃣opposition active ou passive de beaucoup de médecins 2️⃣conséquence directe un modèle économique non viable https://t.co/hSJcMYMzTz
@Syndicat_UNIPA @SarahMarini8 @DevictorJulie
2
6
9
Potential global impact of SGLT2-inhibitors. Prevent and postpone ~8 million worsening HF events and cardiovascular ☠️ over 3 years. @HFA_President #EJHF @EJHFEiC @_antocannata @escardio @ESC_Journals @HanCardiomd @DjawidHashemi @MarcoMetra
1
44
99
ECHO Confocal has arrived, learn more about how our latest microscope will bring high-resolution imaging to the lab.
13
50
632
Pulmonary vein stenosis can arise from several etiologies, including congenital, acquired & iatrogenic sources. PVS presents insidiously, leading to significant delays in diagnosis. Read more on PVS in #JACC: https://t.co/OeDTSMBqDj
0
58
187
I'm beyond excited to announce the Clinical Trials in HF Course. 3 Days. Learn how to: ▶️ how to design trials ▶️ how to analyze data ▶️ how to read correct literature ▶️ practice @GMCRosano @MarcoMetra @_antocannata @SotiriaLiori @ARakisheva @GianluSava @cardioceptor
2
32
67
On May 26, the @US_FDA approved #sotagliflozin, the first dual SGLT-1/2 inhibitor for #HF treatment (regardless of EF). 🆕 study evaluated the eligibility for sotagliflozin in a real-world 🇸🇪 population ⤵️ https://t.co/GYMdfSX6eF
#EHJPharmacotherapy @AgewallStefan @ESC_Journals
0
11
27